LSV Asset Management Trims Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

LSV Asset Management decreased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 2.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 469,700 shares of the medical equipment provider's stock after selling 13,130 shares during the quarter. LSV Asset Management owned about 0.68% of Lantheus worth $42,019,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new position in shares of Lantheus during the 3rd quarter valued at $25,000. Kestra Investment Management LLC bought a new stake in Lantheus in the fourth quarter valued at $27,000. Summit Securities Group LLC acquired a new position in shares of Lantheus during the fourth quarter valued at about $37,000. UMB Bank n.a. boosted its position in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares in the last quarter. Finally, World Investment Advisors LLC acquired a new stake in shares of Lantheus in the 3rd quarter valued at about $60,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have issued reports on LNTH. Truist Financial increased their price target on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. B. Riley cut their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. JMP Securities restated a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Finally, The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective for the company. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $129.43.

Lantheus Trading Up 0.0 %

Shares of LNTH traded up $0.03 during trading hours on Thursday, reaching $100.55. 176,142 shares of the stock traded hands, compared to its average volume of 952,624. Lantheus Holdings, Inc. has a 52 week low of $61.46 and a 52 week high of $126.89. The stock has a fifty day simple moving average of $94.71 and a 200 day simple moving average of $95.61. The company has a market cap of $6.89 billion, a price-to-earnings ratio of 16.71 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.